Alivus Life Sciences Ltd (ALIVUS) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- Alivus Life Sciences Ltd reported a robust revenue of 588 crores for Q2 FY26, marking a healthy 16% year-on-year growth, primarily driven by strong performance in its non-GPL business.
- The non-GPL business demonstrated exceptional growth of 39.7%, largely attributed to successful new product launches and favorable product mix.
- Overall growth was partially moderated by a decline in the GPL segment, which was impacted by customer inventory rationalization, though management anticipates a rebound in H2 FY26.
- The company achieved broad-based growth across key regions, with emerging markets, Latin America, Japan, Europe, and India (excluding GPL) emerging as significant contributors.
- Gross margin for the quarter improved to 57.7%, an increase of 110 basis points year-on-year, driven by rationalized input costs, new product launches, and a favorable product mix.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.